Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials
Event summary
- Alpha Tau's Alpha DaRT achieved 100% local disease control in pooled analysis of two first-in-human trials for pancreatic cancer.
- Favorable safety profile observed with only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks.
- Results presented at Digestive Disease Week (DDW) 2026, marking the first oral presentation of Alpha DaRT at a premier gastroenterology conference.
- Trials included heavily pre-treated patients, some ineligible for chemotherapy and others who had received up to four prior lines of chemotherapy.
- Alpha DaRT delivered via outpatient endoscopic ultrasound (EUS)-guided procedure, designed for seamless integration into standard GI endoscopy workflow.
The big picture
Alpha Tau's Alpha DaRT represents a significant advancement in the treatment of pancreatic cancer, a disease historically resistant to radiation therapy. The 100% local disease control rate achieved in heavily pre-treated patients underscores the potential of intratumoral alpha-emitting radiotherapeutics to address a critical unmet need. The favorable safety profile and the procedure's integration into standard GI workflows position Alpha DaRT as a compelling option in oncology's most challenging indications.
What we're watching
- Clinical Adoption
- How the seamless integration of Alpha DaRT into existing GI endoscopy workflows will affect its clinical adoption.
- Regulatory Pathway
- Whether the favorable safety and efficacy data will accelerate regulatory approvals for Alpha DaRT in pancreatic cancer.
- Market Differentiation
- The pace at which Alpha DaRT can differentiate itself from other systemic therapies and chemotherapy regimens in the pancreatic cancer market.
Related topics